



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** Anti-HTLV-1 Tax Hybridoma (168B17-46-70)

**Catalog Number:** 1314

**Lot Number:** 10/4/91

**Release Category:** A

**Provided:** 8 x 10<sup>6</sup> cells/vial

**Isotype:** Undetermined

**Propagation Medium:** RPMI 1640 supplemented with 50 µM β-mercaptoethanol, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 90%; fetal bovine serum, 10%.

**Freeze Medium:** Propagation medium, 90%; DMSO, 10%.

**Growth Characteristics:** Cells grow in suspension.

**Description** Balb/c mouse splenocyte x P3X63 Ag8.453 myeloma

**Special Characteristics:** Cloned from fusion parent 168B17 or 168A51. Hybridomas secrete monoclonal antibodies that recognize both native and recombinant HTLV-I Tax. A recombinant *E. coli*-derived Tax protein was used as immunogen. Antibody produced by the hybridoma reacts with Tax in Western blots and immunoprecipitation assays.

**Sterility:** Negative for mycoplasma, bacteria and fungi.

**Recommended Storage:** Liquid nitrogen

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Contributor:** Dr. Beatrice Langton, Berlex Biosciences.

**References:** Langton BC, Sliwkowski M, Tran KV, Knapp S, Keitelman E, Smith C, Wallingford S, Liu H-L, Ralston JS, Brandis J, Coates S. Development and characterization of monoclonal antibodies to the HTLV-I Tax (P40X) protein. *Med Virol* **8**:295, 1988.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: (specify hybridoma) from Dr. Beatrice Langton." Also include the reference cited above in any publications.

**Research Chart**

Hybridoma	Cat. #	Lot #	Provided	Isotype
168A51-2 (TAb 173)	1316	4 021096	5.2 x 10 <sup>6</sup> cells/vial	IgG2a
168A51-42 (TAb 176)	1318	4 041567	3.6 x 10 <sup>6</sup> cells/vial	IgG2a
168B17-46-34 (TAb 169)	1312	2 10/2/91	8 x 10 <sup>6</sup> cells/vial	Undetermined
168B17-46-50 (TAb 170)	1313	2 10/1/91	8 x 10 <sup>6</sup> cells/vial	Undetermined
168B17-46-70 (TAb 171)	1314	2 10/4/91	8 x 10 <sup>6</sup> cells/vial	Undetermined
168B17-46-92 (TAb 172)	1315	2 10/7/91	8 x 10 <sup>6</sup> cells/vial	Undetermined

**Last Updated** June 05, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.